Snapshot · The Peter Attia Drive
GLP-1 agonists didn't launch claiming to treat diabetes, obesity, heart disease, and neurodegeneration simultaneously — they proved one indication rigorously and then earned additional ones as evidence accumulated over years.
Where this was said
At 21:18 · chapter starts 20:45
Nick raises a natural devil's advocate question: couldn't expanding claims across multiple therapeutic areas suggest a genuinely broad biological mechanism rather than be a warning sign? Peter is unequivocal. A drug can have broad effects, but only when it hits a fundamental, well-characterized pathway and earns that breadth through evidence. GLP-1 agonists are the model: they started with one indication, proved it rigorously, and then accumulated additional indications as evidence mounted over years. BPC-157 has done the exact opposite — wound healing became tendons, ligaments, muscle, gut disease, inflammation, pain, performance, recovery, and even multiple sclerosis, all without nailing down the first claim in a human trial. [1] — Peter Attia "Real drugs earn new indications through rigorous sequential trials. BPC-157 did the opposite — its claimed benefits expanded from wound hea…" 20:50 The pattern that most troubles Peter is that the missing evidence is not a matter of resources or time; human RCTs are possible but aren't happening, or are happening and the results aren't being published. Legitimate drug development narrows uncertainty over time. Bad or absent science expands claims instead — and BPC-157 has been on the second track for three decades.
Real drugs earn new indications through rigorous sequential trials. BPC-157 did the opposite — its claimed benefits expanded from wound healing to tendons, gut, inflammation, performance, and MS without ever proving a single human indication. Expanding claims without narrowing uncertainty is the signature of a marketing campaign.
Making the first hour of your day high-cortisol and the last hour low-cortisol is described as the single most impactful daily habit for mood, focus, alertness, stress resilience, and sleep quality.
A Washington University in St. Louis study found that a great night's sleep produces attention-improvement effects effectively equal to Ritalin.
In the 4 to 6 hours after exercise, dopamine and norepinephrine are elevated, making you more alert and better able to focus — unless you've exercised to exhaustion.
The physiological sigh — two big inhales followed by a full exhale — was discovered by physiologists in the 1930s and is the fastest way to reduce autonomic arousal.
Doing just 10 deliberate exhales throughout the day can significantly elevate heart rate variability by the evening, by repeatedly activating the vagal sinoatrial node pathway.
For nicotine to have a genuine cognitive-enhancing effect rather than merely rescuing withdrawal deficit, Huberman recommends using it only once or twice per week at 3–6 mg.
Because vaping can be done anywhere and is more palatable, people consume far more nicotine via vaping than they ever did smoking, potentially making vaping more dangerous in aggregate despite being safer per puff.
Huberman reported that two injections of approximately 100–200 micrograms of BPC-157 eliminated persistent shoulder pain that had resisted months of other interventions.
Huberman reported that on nights he used the peptide pinealon, he achieved 2.5 to 3 hours of REM sleep inside 6 hours — an unusually high proportion normally only found in the final hours of longer sleep.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.